Tolerability and acceptance study of two oral hydrocortisone magistral formulations for pediatrics

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519149-31-00

Acronym

HIDROGUM21

Enrollment

Registered

2024-10-31

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency).

Brief summary

The sensory acceptability of the formulation.

Interventions

DRUGHYDROCORTISONE PH. EUR.

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
The sensory acceptability of the formulation.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026